Exclusive: Two ex-Recursion leaders start Noetik in a bid to fix the broken funnel in cancer drug research

Two former leaders of Recursion Pharmaceuticals have started their own biotech startup, hoping to bring a similar data-obsessed mentality to cancer research.

The San Francisco-based company called Noetik launched Thursday, announcing a $14 million seed round led by DCVC. Its two co-founders are CEO Ron Alfa, formerly head of research…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks